Deschatelets Pascal 4

What Happened

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals (APLS), sold 5,928 shares on January 22, 2026 at $21.77 per share, generating proceeds of approximately $129,025. The Form 4 reports the sale as an open-market/private sale and is linked to tax withholding related to recently released RSUs.

Key Details

• Transaction date and price: Jan 22, 2026 — 5,928 shares at $21.77 each (total ≈ $129,025).
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — shares sold to cover tax withholding on Restricted Stock Units released Jan 21, 2026.
• Transaction code: S (Sale); filing accession 0001492422-26-000058.
• Timeliness: Filed Jan 23, 2026 (one day after the transaction) — appears timely.

Context

• This sale was to satisfy tax withholding on vested RSUs, a routine administrative transaction that does not necessarily indicate the insider’s view on the company. Purchases are generally more indicative of bullish sentiment; this filing documents a typical withholding-related sale.